Unapproved product leads to death

July 31, 2006

The FDA has issued a warning against bismacine, also called chromacine, after use of the unapproved product led to one death, one hospitalization, and several injuries. The product contains high concentrations of bismuth and is not a pharmaceutical.

Unapproved product leads to death

The FDA has issued a warning against bismacine, also called chromacine, after use of the unapproved product led to one death, one hospitalization, and several injuries. The product contains high concentrations of bismuth and is not a pharmaceutical. The drug is reportedly mixed by druggists into an injectable form and used to treat Lyme disease by people claiming to be physicians. There are reports of individuals who have experienced serious adverse events, including cardiovascular collapse and kidney failure as a result of treatment with the product. The FDA is advising consumers and healthcare providers not to use bismacine. Meanwhile, the agency will evaluate product suppliers and take additional action if necessary.

To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.